Martela Oyj: Managers' transactions
Person subject to the notification requirement
Name: Lehtonen, Kalle
Position: Chief Financial Officer
Issuer: Martela Plc
Notification type: INITIAL NOTIFICATION
Reference number: 21011/7/6
Transaction date: 2022-11-04
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
Nature of the transaction: DISPOSAL
(1): Volume: 1902 Unit price: 2.6056 EUR
(1): Volume: 1902 Volume weighted average price: 2.6056 EUR
tel +358 400 539 968
Our strategic direction is defined by our mission “Better working” and our vision “People-centric workplaces”. Martela provides people centric workplaces where the users and their wellbeing are in the core. We focus on the Nordic countries, as the Nordic countries are forerunner in hybrid working environments with common open work culture background and needs.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
BioGX Launches 'pixl™' Portable qPCR Platform Ex-US With Expanded Test Menu for Infectious Diseases8.12.2022 20:00:00 CET | Press release
BIRMINGHAM, Ala., Dec. 08, 2022 (GLOBE NEWSWIRE) -- BioGX, a global provider of easy molecular diagnostic solutions since 2007, announced the Ex-US commercial release of its portable pixl™ qPCR real-time PCR platform for use with BioGX CE-IVD marked assays, enabling global access and complementing the recent US FDA EUA expanded use of Xfree™ COVID-19 Direct RT-PCR on the pixl. The pixl instrument is a benchtop 4-channel, 16-well, RT-PCR instrument that supports rapid turnaround times for batches of up to 16 samples, with integrated results interpretation on a device with the compact footprint of a touchpad. "pixl, combined with our unique Xfree chemistry, offers a low-cost direct-sample-to-answer PCR solution on a portable, compact device. pixl will provide broader access to clinical laboratories for decentralized PCR testing, enabling faster, better, low-cost near-patient molecular diagnostics," said Shazi Iqbal, Ph.D., CEO of BioGX. This platform was previously CE-IVD marked and can
Notification under Chapter 9, Section 10 of the Finnish Securities Market Act: holdings of The Goldman Sachs Group, Inc. in Nokia Corporation exceeded 5%8.12.2022 19:00:00 CET | Press release
Notification under Chapter 9, Section 10 of the Finnish Securities Market Act: holdings of The Goldman Sachs Group, Inc. in Nokia Corporation exceeded 5% Nokia Corporation Stock Exchange Release 8 December 2022 at 20:00 EET Notification under Chapter 9, Section 10 of the Finnish Securities Market Act: holdings of The Goldman Sachs Group, Inc. in Nokia Corporation exceeded 5% According to a notification received under Chapter 9, Section 5 of the Finnish Securities Market Act (FSMA) by Nokia Corporation, the direct and indirect holdings of The Goldman Sachs Group, Inc. in Nokia have on 2 December 2022 exceeded 5% of the total number of shares and voting rights of Nokia. According to the notification received by Nokia, the holdings of The Goldman Sachs Group, Inc. in Nokia on 2 December 2022, directly and through its controlled undertakings and funds was equivalent to a total of 293,966,891 shares, corresponding to approximately 5.22% of the total number of shares and voting rights of Nok
Grant of Warrants8.12.2022 18:47:01 CET | Press release
December8, 2022 Announcement no. 18 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, December 8, 2022, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) has, in accordance with its current authorization to issue warrants to key employees of BioPorto, today issued 1,200,000 warrants for the subscription of an equal number of shares. The warrants are issued in accordance with the Company’s remuneration policy and the authorization in section 18 a of the Articles of Association. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 2.55 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants vest over a four-year period. The warrants include conditions on claw-back in case of e.g., erroneous financial information and provisions on accelerated vesting in case of e.g., a takeover bid and/or business combinations. Detailed terms of the new and existing warr
Volta Finance Limited - Dividend Declaration8.12.2022 18:15:00 CET | Press release
Volta FinanceLimited (VTA/VTAS) Dividend Declaration NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Guernsey, 8 December 2022 Volta Finance Limited ("the Company") hereby announces a fourth interim dividend for the financial year commencing 1 August 2021. The Company announces that it has declared a quarterly interim dividend of €0.12 per share payable on 26 January 2023 amounting to approximately €4.42 million, equating approximately to an annualised 8% of net asset value. The ex-dividend date is 29 December 2022 with a record date of 30 December 2022. The Company has arranged for its shareholders to be able to elect to receive their dividends in either Euros or Pounds Sterling. Shareholders will, by default, receive their dividends in Euros, unless they have instructed the Company’s Registrar, Computershare Investor Services (Guernsey) Limited (“Computershare”), to pay dividends in Pounds Sterling. Such instructions may be given to Com
Ilkka Oyj – Acquisition of own shares on 8 December 20228.12.2022 18:00:00 CET | Press release
ILKKA OYJ, STOCK EXCHANGE RELEASE, 8 December 2022 at 19:00 EET IlkkaOyj – Acquisition of own shares on 8 December 2022 At Nasdaq Helsinki Ltd: Date8 December 2022Exchange transactionBuyShare trading codeILKKA2Amount, shares 1,400Average price/share, EUR3.6440Total cost, EUR5,101.60 The company holds a total of 4,317 of its own shares (ILKKA2) including the shares acquired on 8 December 2022. Detailed information concerning the acquisition is attached to this stock exchange release. On behalf of Ilkka Oyj DANSKE BANK A/S, FINLAND BRANCH Jonathan Nyberg Antti Väliaho Additional information Olli Pirhonen, CEO, Ilkka Oyj, tel. +358 40 766 5418 www.ilkka.com Attachment Ilkka buyback 8.12.2022